Health Care · Pharmaceutical Preparations

TNXP Tonix Pharmaceuticals Holding Corp. SEC Filings & Insider Trading Activity 2026

company
CIK 1430306121 filings
Russell 2000

TNXP at a glance

Tonix Pharmaceuticals Holding Corp. (TNXP, SEC CIK 1430306) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Tonix Pharmaceuticals Holding Corp. (TNXP) reported revenue of $13.1 million (up 29.8% from FY2024) and a net loss of $124.0 million. Diluted EPS was -$14.57.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Tonix Pharmaceuticals Holding Corp. (TNXP) shares worth $49.2 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by LEDERMAN SETH on November 11, 2026 of 5,000 shares at $4.05 per share.
  • In the last 90 days, TNXP insiders reported 2 open-market purchases ($48K) and 0 open-market sales ($0) on Form 4, a net purchase of $48K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$13.1M
+29.8% vs prior year
Insiders · 90 days
2 buys · 0 sells
Net +$48K
13F holders
23 funds
$49.2M · +2 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New legal risk: DRL’s October 1, 2026 paragraph IV challenge to four TONMYA patents expiring March 14, 2034
  • Patent litigation deadline: 45 days to seek the 30-month FDA approval stay
  • Revenue risk: Generic TONMYA could reduce sales volume and pricing after regulatory exclusivity expires in August 2028
  • New operational risk: AI inaccuracies could misdirect resources or delay development and regulatory submissions
  • New compliance risk: Evolving AI laws may increase compliance costs or limit acceptance of AI-supported analyses

Management Discussion & Analysis

  • Quarterly revenue $17.2M, up from $3.3M YoY, driven by TONMYA launch
  • TONMYA revenue $15.0M, versus Zembrace SymTouch $1.5M and $2.6M YoY
  • Operating loss $55.4M vs $33.1M; net loss $53.3M vs $32.0M YoY
  • Cash $162.8M; operating cash used $125.6M, financing provided $82.0M through nine months
  • Resources expected to last into early third quarter 2027, with additional funding required; going-concern substantial doubt

AI summary of the TNXP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 8.01: Other Events

  • DRL filed a Paragraph IV ANDA challenging four Orange Book patents covering TONMYA 2.8 mg
  • Tonix sued DRL for patent infringement in New Jersey on November 13, 2026
Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Tonix announced operating results for the quarter ended September 30, 2026
  • Detailed financial figures and management commentary are in Exhibit 99.01, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • TONMYA net sales reached approximately $15.0 million, up 37% quarter-over-quarter, with prescriptions up 28% to 16,375
  • Coverage expanded to approximately 166 million lives, or 53% of U.S. covered lives, supporting commercial traction
Filed Oct 15, 2026Full analysis →

Item 8.01: Other Events

  • Item 8.01 incorporates the Item 2.02 earnings disclosure by reference
  • Investor focus remains on the separate Item 2.02 exhibit for financial results or operating updates

Item 2.02: Results of Operations and Financial Condition

  • Preliminary Q3 2026 TONMYA net revenue estimated at $14.0 million to $15.0 million
  • Cash and cash equivalents approximately $162.8 million as of September 30, 2026

AI summaries of TNXP 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TNXP

Don't miss the next TNXP filing

  • Alerts as it files. A push when TNXP files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TNXP, by share count.
  • Ask anything. An AI agent that reads every TNXP filing and answers with sources.

TNXP alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
LEDERMAN SETHBuyNov 11, 2026$4.05
LEDERMAN SETHBuyAug 27, 2026$13.79
BAGGER RICHARD HBuyAug 20, 2026$12.60
SAENGER BRADLEYJJun 30, 2026$10.91
Taylor Carolyn E.BuyJun 12, 2026$10.55
LEDERMAN SETHBuyJun 9, 2026$11.79
Stillwell Richard NewcombBuyJun 8, 2026$11.65
Taylor Carolyn E.AMay 12, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$10.1M$13.1M
Operating Income-$118.4M-$136.7M-$125.7M
Net Income-$116.7M-$130.0M-$124.0M
Op. Margin--1354.3%-959.1%
Net Margin--1288.3%-946.2%
Balance Sheet
Total Assets-$162.9M$277.2M
Equity-$139.6M$245.2M
ROE--93.2%-50.6%
Per Share
EPS-$-176.60$-14.57
Cash Flow
Operating CF-$102.0M-$60.9M-$99.8M
CapEx$7.9M$120K$3.4M

Source: XBRL data in Tonix Pharmaceuticals Holding Corp. (TNXP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TNXP share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TNXP shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$49.2M
Q2 202621$64.6M
Q1 202618$40.6M
Q4 202516$33.8M
Q3 202513$41.7M
Q2 202515$34.6M
Q1 20257$3.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 113 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TNXP filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 13, 2026Analysis-
4Nov 12, 2026--
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
8-KOct 15, 2026Analysis-
8-KOct 2, 2026Analysis-
8-KSep 22, 2026Analysis-
8-KSep 8, 2026Analysis-
4Aug 31, 2026--
4Aug 24, 2026--
8-KAug 18, 2026Analysis-
SC 13GAug 13, 2026-
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
8-KAug 3, 2026Analysis-
8-KJul 21, 2026Analysis-
8-KJul 13, 2026Analysis-
4Jul 9, 2026--
8-KJun 29, 2026Analysis-
SC 13GJun 15, 2026-
4Jun 15, 2026--
4Jun 9, 2026-
4Jun 9, 2026-
8-KJun 8, 2026-
8-KMay 27, 2026-

Related Health Care companies

All Health Care →

TNXP SEC filings: frequently asked questions

Are TNXP insiders buying or selling?

In the last 90 days, Tonix Pharmaceuticals Holding Corp. (TNXP) officers, directors and 10% owners reported 2 open-market purchases worth $47,855 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TNXP stock?

As of September 30, 2026, the largest Tonix Pharmaceuticals Holding Corp. (TNXP) holders among the 13F filers tracked by SignalX were BlackRock ($15.2 million), Millennium Management ($8.0 million), Vanguard Capital Management LLC ($6.7 million), AQR Capital Management ($6.5 million), Citadel Advisors LLC ($3.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TNXP's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Tonix Pharmaceuticals Holding Corp. (TNXP) reported revenue of $13.1 million (up 29.8% from FY2024) and a net loss of $124.0 million. Diluted EPS was -$14.57. The figures come from the XBRL data in the 10-K.

What did TNXP report in its latest 8-K?

Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K on November 13, 2026 reporting Item 8.01 (Other Events). DRL filed a Paragraph IV ANDA challenging four Orange Book patents covering TONMYA 2.8 mg.

What are the latest TNXP SEC filings?

Tonix Pharmaceuticals Holding Corp. (TNXP) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on November 12, 2026.

What is TNXP's SEC CIK number?

Tonix Pharmaceuticals Holding Corp. (TNXP)'s SEC Central Index Key (CIK) is 1430306. EDGAR lists every TNXP filing under that number.

Ask anything about TNXP

The research agent reads TNXP's filings, financials, insider trades and 13F holders, then answers with sources.